Sandro Pignata
#164,580
Most Influential Person Now
Researcher
Sandro Pignata's AcademicInfluence.com Rankings
Sandro Pignatacomputer-science Degrees
Computer Science
#9758
World Rank
#10237
Historical Rank
Computational Linguistics
#2399
World Rank
#2423
Historical Rank
Machine Learning
#4361
World Rank
#4411
Historical Rank
Artificial Intelligence
#4712
World Rank
#4775
Historical Rank
Download Badge
Computer Science
Sandro Pignata's Degrees
- Masters Artificial Intelligence Stanford University
- Bachelors Computer Science University of California, Berkeley
Similar Degrees You Can Earn
Why Is Sandro Pignata Influential?
(Suggest an Edit or Addition)Sandro Pignata's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients (1998) (1263)
- Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. (2017) (1151)
- Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies: results in 123 patients. (1999) (1128)
- Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial (2017) (1039)
- Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. (2019) (829)
- Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. (2010) (509)
- Prospective validation of the CLIP score, a new prognostic system for cirrhotic patients with hepatocellular carcinoma (RE: Hepatology 2000, 32/3: 679-80) (2000) (414)
- ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†. (2019) (385)
- Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. (2014) (322)
- Incorporation of pazopanib in maintenance therapy of ovarian cancer. (2014) (304)
- The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients with Cervical Cancer (2018) (277)
- Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. (2008) (266)
- Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. (2019) (241)
- ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. (2019) (207)
- Tamoxifen in treatment of hepatocellular carcinoma: a randomised controlled trial (1998) (200)
- The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology guidelines for the management of patients with cervical cancer. (2018) (198)
- Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial. (2016) (190)
- Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial. (2011) (181)
- Clinical Trials in Recurrent Ovarian Cancer (2011) (177)
- A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis (2013) (171)
- ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease (2019) (163)
- Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer. (2022) (157)
- Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study. (2004) (153)
- Gemcitabine versus bacille Calmette‐Guérin after initial bacille Calmette‐Guérin failure in non‐muscle‐invasive bladder cancer (2010) (150)
- Antitumor Activity and Safety of Pembrolizumab in Patients with Advanced Recurrent Ovarian Cancer: Results from the Phase 2 KEYNOTE-100 Study. (2019) (150)
- The forefront of ovarian cancer therapy: update on PARP inhibitors. (2020) (139)
- Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial. (2015) (136)
- Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. (2021) (132)
- Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer. (2009) (129)
- Immunotherapy in ovarian, endometrial and cervical cancer: State of the art and future perspectives. (2017) (113)
- Long-term follow-up is crucial after treatment for granulosa cell tumours of the ovary (2013) (109)
- Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39) (2021) (109)
- A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2-C colorectal carcinoma. (2016) (107)
- Effect of pregnancy on the clinical course of a cohort of women with inflammatory bowel disease. (1996) (106)
- PARP inhibitors in ovarian cancer. (2019) (106)
- Tumor genotype and immune microenvironment in POLE-ultramutated and MSI-hypermutated Endometrial Cancers: New candidates for checkpoint blockade immunotherapy? (2016) (101)
- Randomized Phase III Trial of Irinotecan Plus Cisplatin Compared With Paclitaxel Plus Carboplatin As First-Line Chemotherapy for Ovarian Clear Cell Carcinoma: JGOG3017/GCIG Trial. (2016) (99)
- Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study. (2016) (91)
- Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: The Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study (2006) (89)
- Latest clinical evidence and further development of PARP inhibitors in ovarian cancer (2018) (89)
- Identification of a distinct population of CD133+CXCR4+ cancer stem cells in ovarian cancer (2015) (89)
- Concomitant CXCR4 and CXCR7 expression predicts poor prognosis in renal cancer. (2010) (88)
- Inhibitory effects of anti-CXCR4 antibodies on human colon cancer cells (2005) (87)
- Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients. (2003) (86)
- The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients With Cervical Cancer. (2018) (84)
- Treatment of recurrent ovarian cancer. (2017) (81)
- Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. (2021) (80)
- Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (AEOC): Results of an international Intergroup trial (AGO-OVAR16). (2013) (80)
- Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy. (2015) (79)
- Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation. (2020) (79)
- First-line treatment of advanced ovarian cancer: current research and perspectives (2010) (77)
- Randomized Phase II Trial of Ridaforolimus in Advanced Endometrial Carcinoma. (2015) (77)
- Transforming growth factor alpha, amphiregulin and cripto-1 are frequently expressed in advanced human ovarian carcinomas. (2002) (75)
- Detection of circulating tumor cells in carcinoma patients by a novel epidermal growth factor receptor reverse transcription-PCR assay. (2000) (73)
- Management of Platinum-Resistant, Relapsed Epithelial Ovarian Cancer and New Drug Perspectives. (2019) (71)
- Hepatocellular Carcinoma: Systemic Treatments (2002) (68)
- Evaluation of a Streamlined Oncologist-Led BRCA Mutation Testing and Counseling Model for Patients With Ovarian Cancer. (2018) (65)
- Effect of Chemotherapy with 5-Fluorouracil on Intestinal Permeability and Absorption in Patients with Advanced Colorectal Cancer (2001) (64)
- Phase II study of cisplatin and vinorelbine as first-line chemotherapy in patients with carcinoma of the uterine cervix. (1999) (64)
- A randomized, phase III study of carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in relapsed platinum-sensitive ovarian cancer (OC): CALYPSO study of the Gynecologic Cancer Intergroup (GCIG). (2009) (64)
- Effect of aspirin on cell proliferation and differentiation of colon adenocarcinoma Caco‐2 cells (1997) (64)
- ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer. (2015) (64)
- Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: The Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study (2006) (63)
- A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study. (2008) (63)
- Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real‐world results from an expanded access programme (2018) (63)
- Regulatory T cells, interleukin (IL)‐6, IL‐8, Vascular endothelial growth factor (VEGF), CXCL10, CXCL11, epidermal growth factor (EGF) and hepatocyte growth factor (HGF) as surrogate markers of host immunity in patients with renal cell carcinoma (2013) (62)
- Hepatic Resection and Percutaneous Ethanol Injection as Treatments of Small Hepatocellular Carcinoma: A Cancer of the Liver Italian Program (CLIP 08) Retrospective Case–Control Study (2003) (61)
- Chemotherapy in epithelial ovarian cancer. (2011) (60)
- Chemotherapy plus or minus bevacizumab for platinum-sensitive ovarian cancer patients recurring after a bevacizumab containing first line treatment: The randomized phase 3 trial MITO16B-MaNGO OV2B-ENGOT OV17. (2018) (58)
- Gynecologic Cancer InterGroup (GCIG) Consensus Review for Ovarian and Primary Peritoneal Low-Grade Serous Carcinomas (2014) (58)
- Characteristics at presentation and outcome of hepatocellular carcinoma (HCC) in the elderly. A study of the Cancer of the Liver Italian Program (CLIP). (2006) (56)
- Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trial. (2016) (55)
- Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: Interim results from the phase 2 KEYNOTE-100 study. (2018) (55)
- Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study. (2017) (53)
- The role of staging and adjuvant chemotherapy in stage I malignant ovarian germ cell tumors (MOGTs): the MITO-9 study (2016) (52)
- Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group. (2010) (52)
- Ovarian cancer in the elderly. (2004) (51)
- Targeting CXCR4 reverts the suppressive activity of T-regulatory cells in renal cancer (2017) (50)
- Is human hepatocellular carcinoma a hormone-responsive tumor? (2008) (50)
- The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients With Cervical Cancer (2018) (50)
- Treatment with olaparib monotherapy in the maintenance setting significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: Results from the phase III SOLO2 study (2017) (50)
- Tamoxifen in the treatment of hepatocellular carcinoma: 5-year results of the CLIP-1 multicentre randomised controlled trial. (2002) (50)
- Endometrial Cancer Stem Cells: Role, Characterization and Therapeutic Implications (2019) (49)
- Clinical Trials with Pegylated Liposomal Doxorubicin in the Treatment of Ovarian Cancer (2013) (48)
- Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study (2008) (48)
- Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer. (2013) (48)
- Deregulation of HOX B13 expression in urinary bladder cancer progression. (2013) (48)
- Treatment of recurrent epithelial ovarian cancer (2009) (47)
- Expression of insulin-like growth factor (IGF)-II and IGF-I receptor during proliferation and differentiation of CaCo-2 human colon carcinoma cells. (1994) (47)
- Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial. (2021) (46)
- Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives. (2019) (46)
- Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome. (2019) (46)
- MILO/ENGOT-ov11: Binimetinib Versus Physician’s Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum (2020) (46)
- New treatment approaches in renal cell carcinoma (2009) (45)
- Follow-up with CA125 after primary therapy of advanced ovarian cancer: in favor of continuing to prescribe CA125 during follow-up. (2011) (45)
- Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer. (2019) (44)
- Prognostic value of serum biological markers in patients with hepatocellular carcinoma. (2001) (44)
- Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. (2022) (44)
- Carboplatin-paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 - A randomized phase II trial. (2019) (43)
- Activity of chemotherapy in mucinous epithelial ovarian cancer: a retrospective study. (2005) (42)
- A randomized phase II (RP2) trial of ridaforolimus (R) compared with progestin (P) or chemotheraphy (C) in female adult patients with advanced endometrial carcinoma. (2011) (42)
- Gynecological malignancies in elderly patients: is age 70 a limit to standard-dose chemotherapy? An Italian retrospective toxicity multicentric study. (2002) (42)
- High HMGA2 Expression and High Body Mass Index Negatively Affect the Prognosis of Patients With Ovarian Cancer (2013) (40)
- Phase I study with weekly cisplatin-paclitaxel and concurrent radiotherapy in patients with carcinoma of the cervix uteri. (2000) (40)
- Angiogenesis: a promising therapeutic target for ovarian cancer. (2012) (40)
- Treatment of recurrent ovarian cancer. (2017) (39)
- Metastases to the breast: role of fine needle cytology samples. Our experience with nine cases in 2 years. (2008) (39)
- Constitutive Insulin-like Growth Factor-II Expression Interferes with the Enterocyte-like Differentiation of CaCo-2 Cells (*) (1996) (39)
- Is surgical restaging indicated in apparent stage IA pure ovarian dysgerminoma? The MITO group retrospective experience. (2011) (39)
- Gynecologic Cancer InterGroup (GCIG) Consensus Review for Cervical Adenocarcinoma (2014) (39)
- Association of PD-L1 expression and gene expression profiling with clinical response to pembrolizumab in patients with advanced recurrent ovarian cancer: Results from the phase II KEYNOTE-100 study. (2018) (39)
- Randomized phase II trial of carboplatin-paclitaxel (CP) compared to carboplatin-paclitaxel-bevacizumab (CP-B) in advanced (stage III-IV) or recurrent endometrial cancer: The MITO END-2 trial. (2015) (38)
- Quality of life: gynaecological cancers. (2001) (38)
- Soluble Interleukin-2 Receptor Levels in Hepatocellular Cancer: a More Sensitive Marker Than Alfa Fetoprotein (1999) (38)
- High CXCR4 expression correlates with sunitinib poor response in metastatic renal cancer. (2012) (37)
- Surgical and Medical Treatment of Clear Cell Ovarian Cancer: Results From the Multicenter Italian Trials in Ovarian Cancer (MITO) 9 Retrospective Study (2011) (37)
- Very Early PSA Response to Abiraterone in mCRPC Patients: A Novel Prognostic Factor Predicting Overall Survival (2016) (37)
- Oestradiol and testosterone blood levels in patients with viral cirrhosis and hepatocellular carcinoma (1997) (35)
- Health-related quality of life in recurrent platinum-sensitive ovarian cancer--results from the CALYPSO trial. (2012) (34)
- Olaparib, PARP1 inhibitor in ovarian cancer (2012) (33)
- Inflammatory Indexes as Prognostic and Predictive Factors in Ovarian Cancer Treated with Chemotherapy Alone or Together with Bevacizumab. A Multicenter, Retrospective Analysis by the MITO Group (MITO 24) (2018) (33)
- Trials in progress: IMagyn050/GOG 3015/ENGOT-OV39. A Phase III, multicenter, randomized study of atezolizumab versus placebo administered in combination with paclitaxel, carboplatin, and bevacizumab to patients with newly-diagnosed stage III or stage IV ovarian, fallopian tube, or primary peritoneal (2019) (33)
- A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group (2007) (33)
- The role of immunotherapy in solid tumors: report from the Campania Society of Oncology Immunotherapy (SCITO) meeting, Naples 2014 (2014) (33)
- Carboplatin and Pegylated Liposomal Doxorubicin for Advanced Ovarian Cancer: Preliminary Activity Results of the MITO-2 Phase III Trial (2008) (32)
- Practice patterns of radiotherapy in cervical cancer among member groups of the Gynecologic Cancer Intergroup (GCIG). (2007) (32)
- Extending the Platinum-Free Interval with a Non-Platinum Therapy in Platinum-Sensitive Recurrent Ovarian Cancer (2007) (32)
- Ornithine decarboxylase and diamine oxidase in human colon carcinoma cell line CaCo-2 in culture. (1989) (31)
- Early decline in cancer antigen 125 as a surrogate for progression-free survival in recurrent ovarian cancer. (2011) (31)
- Current knowledge and open issues regarding bevacizumab in gynaecological neoplasms. (2012) (31)
- Uterine serous carcinoma. (2021) (31)
- Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial. (2017) (31)
- Poor outcome of elderly patients with platinum-sensitive recurrent ovarian cancer: results from the SOCRATES retrospective study. (2009) (31)
- European Network of Gynaecological Oncological Trial Groups' Requirements for Trials Between Academic Groups and Pharmaceutical Companies (2010) (31)
- Polyamine uptake by human colon carcinoma cell line CaCo-2. (1990) (31)
- Assessment of Progression-Free Survival as a Surrogate End Point of Overall Survival in First-Line Treatment of Ovarian Cancer (2020) (31)
- Immune Checkpoint Inhibitors: A Promising Choice for Endometrial Cancer Patients? (2020) (31)
- LBA31 Primary results from IMagyn050/GOG 3015/ENGOT-OV39, a double-blind placebo (pbo)-controlled randomised phase III trial of bevacizumab (bev)-containing therapy +/- atezolizumab (atezo) for newly diagnosed stage III/IV ovarian cancer (OC) (2020) (30)
- Safety of cisplatin after severe hypersensitivity reactions to carboplatin in patients with recurrent ovarian carcinoma. (2003) (29)
- First-Line Chemotherapy With Fluorouracil and Folinic Acid for Advanced Colorectal Cancer in Elderly Patients: A Phase II Study (2003) (29)
- A Large, Multicenter, Retrospective Study on Efficacy and Safety of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Ovarian Cancer (MITO RT1 Study): A Collaboration of MITO, AIRO GYN, and MaNGO Groups. (2020) (29)
- Transcriptional activation of the H-ferritin gene in differentiated Caco-2 cells parallels a change in the activity of the nuclear factor Bbf. (1995) (29)
- The role of chemotherapy in locally advanced, metastatic and recurrent cervical cancer. (2004) (28)
- The enterocyte-like differentiation of the Caco-2 tumor cell line strongly correlates with responsiveness to cAMP and activation of kinase A pathway. (1994) (28)
- Cisplatin can be safely administered to ovarian cancer patients with hypersensitivity to carboplatin. (2017) (27)
- Treatment of recurrent epithelial ovarian cancer (2019) (27)
- Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study) (2021) (26)
- Postheparin plasma diamine oxidase in patients with small bowel Crohn's disease. (1988) (25)
- Postheparin plasma diamine oxidase increases in patients with coeliac disease during gluten free diet. (1987) (25)
- Effect of Weekly Paclitaxel With or Without Bevacizumab on Progression-Free Rate Among Patients With Relapsed Ovarian Sex Cord-Stromal Tumors: The ALIENOR/ENGOT-ov7 Randomized Clinical Trial. (2020) (25)
- Predictive Comprehensive Geriatric Assessment in elderly prostate cancer patients: the prospective observational scoop trial results (2017) (25)
- Use of Adjuvant Therapy in Patients with FIGO Stage III Endometrial Carcinoma: A Multicenter Retrospective Study (2011) (24)
- Urotensin II receptor determines prognosis of bladder cancer regulating cell motility/invasion (2014) (24)
- Incorporating Parp-inhibitors in Primary and Recurrent Ovarian Cancer: A Meta-analysis of 12 phase II/III randomized controlled trials. (2020) (24)
- The strong prognostic value of KELIM, a model-based parameter from CA 125 kinetics in ovarian cancer: data from CALYPSO trial (a GINECO-GCIG study). (2013) (24)
- Prognostic role of topoisomerase-IIα in advanced ovarian cancer patients (2008) (24)
- Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study (2018) (23)
- Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial (2006) (23)
- Endocrine treatment of hepatocellular carcinoma. Any evidence of benefit? (1998) (23)
- Efficacy and safety data in elderly patients with metastatic renal cell carcinoma included in the nivolumab Expanded Access Program (EAP) in Italy (2018) (23)
- Patterns of Care for Radiotherapy in Vulvar Cancer: A Gynecologic Cancer Intergroup Study (2009) (23)
- Bevacizumab in ovarian cancer: Focus on clinical data and future perspectives. (2016) (23)
- Assessment of small intestinal damage in patients treated with pelvic radiotherapy. (1998) (23)
- Recommendations for the implementation of BRCA testing in the care and treatment pathways of ovarian cancer patients. (2016) (22)
- Conservative surgery in stage I adult type granulosa cells tumors of the ovary: Results from the MITO-9 study. (2019) (22)
- State of the art about influenza vaccination for advanced cancer patients receiving immune checkpoint inhibitors: When common sense is not enough. (2019) (21)
- A Large, Multicenter, Retrospective Study on Efficacy and Safety Of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Ovarian Cancer (MITO RT1 Study): A Collaboration of MITO, AIRO GYN, and MaNGO Groups. (2019) (21)
- Obesity and Cancer: Biological Links and Treatment Implications. (2017) (21)
- Tamoxifen is not effective in good prognosis patients with hepatocellular carcinoma (2006) (20)
- Practice Patterns of Radiotherapy in Endometrial Cancer Among Member Groups of the Gynecologic Cancer Intergroup (2009) (20)
- Effect of non-steroidal anti-inflammatory drugs on colon carcinoma Caco-2 cell responsiveness to topoisomerase inhibitor drugs (2002) (20)
- Levovist-enhanced Doppler Sonography Versus Spiral Computed Tomography to Evaluate Response to Percutaneous Ethanol Injection in Hepatocellular Carcinoma (2000) (20)
- Long-Term Toxicity and Quality of Life in Patients Treated for Locally Advanced Cervical Cancer (2015) (20)
- Randomized phase III trial of paclitaxel/carboplatin (PC) versus cisplatin/irinotecan (CPT-P) as first-line chemotherapy in patients with clear cell carcinoma (CCC) of the ovary: A Japanese Gynecologic Oncology Group (JGOG)/GCIG study. (2014) (19)
- Cell cycle block at G1-S or G2-M phase correlates with differentiation of Caco-2 cells: effect of constitutive insulin-like growth factor II expression. (1999) (19)
- Immunotherapy in cervix cancer. (2020) (19)
- PAOLA-1: An ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab. (2016) (19)
- A Phase 2 Multicenter Study of Irinotecan and Cisplatinum as Neoadjuvant Treatment in Patients With Locally Advanced Cervical Cancer (2009) (19)
- FEZ1/LZTS1 protein expression in ovarian cancer (2010) (18)
- Detection of high mobility group A2 specific mRNA in the plasma of patients affected by epithelial ovarian cancer (2015) (18)
- 813MO Efficacy of subsequent chemotherapy for patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib vs placebo: The SOLO2/ENGOT Ov-21 trial (2020) (18)
- Final results from the KEYNOTE-100 trial of pembrolizumab in patients with advanced recurrent ovarian cancer. (2020) (18)
- Chemotherapy in squamous cell carcinoma of the cervix uteri: present role and perspectives. (1998) (18)
- Carboplatin plus paclitaxel (CP) versus carboplatin plus stealth liposomal doxorubicin (CLD) in patients with advanced ovarian cancer (AOC): Activity and safety results of the MITO-2 randomized multicenter trial. (2009) (18)
- Single agents should be administered in preference to combination chemotherapy for the treatment of patients over 70 years of age with advanced ovarian carcinoma. (2000) (18)
- Therapeutic options following second-line platinum-based chemotherapy in patients with recurrent ovarian cancer: Comparison of active surveillance and maintenance treatment. (2020) (18)
- Interaction of Putrescine with Nuclear Oligopeptides in the Enterocyte-Like Caco-2 Cells (1999) (18)
- The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer. (2019) (17)
- Rare ovarian tumours: Epidemiology, treatment challenges in and outside a network setting. (2017) (17)
- Modifications in enterocyte diamine oxidase distribution induced by heparin in the rat. (1989) (17)
- Cyclo-Oxygenase Inhibition in Colorectal Adenomas and Cancer (2003) (16)
- Impact of COVID-19 in gynecologic oncology: a Nationwide Italian Survey of the SIGO and MITO groups (2020) (16)
- Postheparin plasma diamine oxidase in subjects with small bowel disease. Diagnostic efficiency of a simplified test. (1988) (16)
- European Network of Gynaecological Oncological Trial Groups’ Requirements for Trials Between Academic Groups and Industry Partners—First Update 2015 (2015) (16)
- The prognostic role of pre-chemotherapy hemoglobin level in patients with ovarian cancer. (2006) (16)
- Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001 (2021) (16)
- Pegylated liposomal doxorubicin combined with carboplatin: a rational treatment choice for advanced ovarian cancer. (2010) (16)
- A randomized, phase III study of carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in relapsed platinum-sensitive ovarian cancer (OC): CALYPSO study of the Gynecologic Cancer Intergroup (GCIG). (2009) (16)
- Testicular and testicular adnexa tumors in the elderly (2013) (15)
- Trabectedin in Ovarian Cancer: is it now a Standard of Care? (2018) (15)
- Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup. (2022) (15)
- Modifications in ornithine decarboxylase and diamine oxidase in small bowel mucosa of starved and refed rats. (1987) (15)
- PARP Inhibitors in Endometrial Cancer: Current Status and Perspectives (2020) (15)
- Second-Line Chemotherapy in Recurrent Clear Cell Ovarian Cancer: Results from the Multicenter Italian Trials in Ovarian Cancer (MITO-9) (2014) (15)
- Pazopanib in Metastatic Renal Cancer: A “Real-World” Experience at National Cancer Institute “Fondazione G. Pascale” (2016) (15)
- An escalating dose finding study of liposomal doxorubicin and vinorelbine for the treatment of refractory or resistant epithelial ovarian cancer. (2003) (14)
- Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: predictive value of DNA-PK and phosphorylated ACC (2016) (14)
- Axitinib after Sunitinib in Metastatic Renal Cancer: Preliminary Results from Italian “Real-World” SAX Study (2016) (14)
- A multicenter, open-label, randomized, phase III study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab versus treatment of physician's choice in patients with advanced endometrial cancer (2021) (14)
- Laparoscopic treatment of a Yolk Sac Tumor: case report and literature review (2013) (13)
- Intravesical chemo-immunotherapy in non muscle invasive bladder cancer. (2013) (13)
- Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer-The GCIG Symptom Benefit Study. (2017) (13)
- Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG (2020) (13)
- Can hepatocellular cancer screening increase the proportion of long-term survivors? (2009) (13)
- INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a multicenter prospective observational study (INVIDIa-2) (2021) (13)
- Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study (2021) (13)
- 1 MILO/ENGOT-OV11: Phase-3 study of binimetinib versus physician’s choice chemotherapy (PCC) in recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum (2019) (13)
- Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge”, Napoli, November 30th 2016 (2017) (13)
- Cyclooxygenase-2 expression is associated with increased size in human sporadic colorectal adenomas. (2005) (12)
- A phase I study of gemcitabine and epirubicin for the treatment of platinum-resistant or refractory advanced ovarian cancer. (2000) (12)
- Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists (2020) (12)
- Homologous recombination repair mutation gene panels (excluding BRCA) are not predictive of maintenance olaparib plus bevacizumab efficacy in the first-line PAOLA-1/ENGOT-ov25 trial (2021) (12)
- Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge 2018” (28–29 November, 2018, Naples, Italy) (2018) (12)
- Release of diamine oxidase into plasma by glycosaminoglycans in rats. (1989) (12)
- Hypergastrinemia in rats with azoxymethane‐induced colon cancers (1995) (12)
- Olaparib Tablets as Maintenance Therapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a BRCA1/2 Mutation (SOLO2/ENGOT-Ov21): A Final Analysis of a Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial (2021) (12)
- Postheparin plasma diamine oxidase values in the follow up of patients with small bowel Crohn's disease. (1991) (12)
- COVID-19 Emergency and Post-Emergency in Italian Cancer Patients: How Can Patients Be Assisted? (2020) (12)
- Phase I clinical trial of liposomal daunorubicin in hepatocellular carcinoma complicating liver cirrhosis. (2000) (12)
- Second-line intra-arterial chemotherapy in advanced pancreatic adenocarcinoma. (2006) (11)
- Pegylated liposomal doxorubicin and carboplatin (C-PLD) versus paclitaxel and carboplatin (C-P) in platinum-sensitive ovarian cancer (OC) patients (pts): Treatment at recurrence and overall survival (OS) final analysis from CALYPSO phase III GCIG trial. (2011) (11)
- Inflammatory indexes as predictive factors for platinum sensitivity and as prognostic factors in recurrent epithelial ovarian cancer patients: a MITO24 retrospective study (2020) (11)
- LBA32 Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer: Results from the phase II innovaTV 204/GOG-3023/ENGOT-cx6 study (2020) (11)
- Is ovarian cancer a targetable disease? A systematic review and meta-analysis and genomic data investigation (2016) (11)
- Mirvetuximab soravtansine (MIRV) in patients with platinum-resistant ovarian cancer with high folate receptor alpha (FRα) expression: Characterization of antitumor activity in the SORAYA study. (2022) (11)
- Apolipoprotein A-I reverse transcriptase-polymerase chain reaction analysis for detection of hematogenous colon cancer dissemination. (1998) (11)
- ENGOT-cx11/KEYNOTE-A18: A phase III, randomized, double-blind study of pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer. (2020) (11)
- 1st Evidence-based Italian Consensus Conference on Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinosis from Ovarian Cancer (2017) (11)
- Subcutaneous seeding of hepatocellular carcinoma after fine-needle percutaneous biopsy. (2001) (11)
- The role of the tumor primary chemosensitivity relative to the success of the medical-surgical management in patients with advanced ovarian carcinomas. (2021) (11)
- Predicting mortality and adverse events in patients with advanced pancreatic cancer treated with palliative gemcitabine-based chemotherapy in a multicentre phase III randomized clinical trial: the APC-SAKK risk scores (2019) (11)
- Mutated Von Hippel-Lindau-renal cell carcinoma (RCC) promotes patients specific natural killer (NK) cytotoxicity (2018) (11)
- Regulation of diamine oxidase expression by ornithine decarboxylase in isolated rat small bowel enterocytes. (1990) (11)
- 723MO Tisotumab vedotin (TV) + carboplatin (Carbo) in first-line (1L) or + pembrolizumab (Pembro) in previously treated (2L/3L) recurrent or metastatic cervical cancer (r/mCC): Interim results of ENGOT-Cx8/GOG-3024/innovaTV 205 study (2021) (11)
- A phase II study of capecitabine in the treatment of ovarian cancer resistant or refractory to platinum therapy: a multicentre Italian trial in ovarian cancer (MITO-6) trial (2009) (10)
- Can we replace adjuvant chemotherapy with surveillance for stage IA-C immature ovarian teratomas of any grade? an international multicenter analysis. (2020) (10)
- Significance of erb-B2 immunoreactivity in cervical cancer. (2006) (10)
- ENGOT-OV44/FIRST study: A randomized, double-blind, adaptive, phase III study of platinum-based therapy with dostarlimab (TSR-042) + niraparib versus standard-of-care (SOC) platinum-based therapy as first-line treatment of stage 3/4 non-mucinous epithelial ovarian cancer (OC). (2019) (10)
- Therapeutic Challenges for Cisplatin-Resistant Ovarian Germ Cell Tumors (2019) (10)
- Updated results from OCTAVIA (front-line bevacizumab, carboplatin and weekly paclitaxel therapy for ovarian cancer). (2014) (10)
- O008/#785 A multicenter, open-label, randomized, phase 3 study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab vs treatment of physician’s choice in patients with advanced endometrial cancer: study 309/keynote-775 (2021) (9)
- Intraperitoneal chemotherapy with carboplatin and recombinant interferon alpha in ovarian cancer. (1994) (9)
- Ovarian Cancer Translational Activity of the Multicenter Italian Trial in Ovarian Cancer (MITO) Group: Lessons Learned in 10 Years of Experience (2020) (9)
- Primary surgical cytoreduction in advanced ovarian cancer: An outcome analysis within the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group. (2016) (9)
- Olaparib as salvage treatment for advanced germ cell tumors after chemotherapy failure: Results of the open-label, single-arm, IGG-02 phase II trial. (2020) (9)
- Safety of front-line bevacizumab (BEV) combined with weekly paclitaxel (wPAC) and q3w carboplatin (C) for ovarian cancer (OC): Results from OCTAVIA. (2012) (9)
- MITO-11: A randomized multicenter phase II trial testing the addition of pazopanib to weekly paclitaxel in platinum-resistant or -refractory advanced ovarian cancer (AOC). (2014) (9)
- Tisotumab vedotin (TV) + pembrolizumab (pembro) in first-line (1L) recurrent or metastatic cervical cancer (r/mCC): Interim results of ENGOT Cx8/GOG 3024/innovaTV 205. (2022) (9)
- Management of kidney cancer patients: 2018 guidelines of the Italian Medical Oncology Association (AIOM) (2019) (9)
- Immunotherapy may protect cancer patients from SARS-CoV-2 infection: a single-center retrospective analysis (2021) (9)
- Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies (2022) (9)
- Surveillance policy for stage IA malignant ovarian germ cell tumors in children and young adults. (2014) (9)
- Lenvatinib Plus Pembrolizumab for Advanced Endometrial Cancer (2022) (9)
- Real-life clinical practice results with vinflunine in patients with relapsed platinum-treated metastatic urothelial carcinoma: an Italian multicenter study (MOVIE-GOIRC 01–2014) (2017) (9)
- A phase 3 trial evaluating efficacy and safety of lenvatinib in combination with pembrolizumab in patients with advanced endometrial cancer. (2019) (9)
- Emerging molecular alterations leading to histology-specific targeted therapies in ovarian cancer beyond PARP inhibitors. (2021) (9)
- Sulindac-induced severe hepatitis. (1988) (8)
- Independent review of AGO-OVAR 12, a GCIG/ENGOT-Intergroup phase III trial of nintedanib (N) in first-line therapy for ovarian cancer (OC). (2014) (8)
- A European, Observational, Prospective Trial of Trabectedin Plus Pegylated Liposomal Doxorubicin in Patients with Platinum‐Sensitive Ovarian Cancer (2020) (8)
- PARP Inhibitors in First-Line Therapy of Ovarian Cancer: Are There Any Doubts? (2020) (8)
- Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study) (2021) (8)
- Power Doppler sonography to evaluate response to percutaneous ethanol injection in hepatocellular carcinoma. (1997) (8)
- 18LBA A GCIG randomized phase III study of carboplatin (C) & pegylated liposomal doxorubicin (PLD) (C-D) vs carboplatin (C) & paclitaxel (P) (C-P): CALYPSO results in partially platinum-sensitive ovarian cancer (OC) patients (2009) (8)
- Genomic Profile and BRCA-1 Promoter Methylation Status in BRCA Mutated Ovarian Cancer: New Insights in Predictive Biomarkers of Olaparib Response (2019) (8)
- Clinical trials and drug cost savings for Italian health service (2020) (8)
- ENGOT-en9/LEAP-001: A phase III study of first-line pembrolizumab plus lenvatinib versus chemotherapy in advanced or recurrent endometrial cancer. (2020) (8)
- New biological treatments for gynecological tumors: focus on angiogenesis (2014) (8)
- A phase I-II study of elacytarabine (CP-4055) in the treatment of patients with ovarian cancer resistant or refractory to platinum therapy (2011) (8)
- AGO-OVAR 16: A phase III study to evaluate the efficacy and safety of pazopanib (PZ) monotherapy versus placebo in women who have not progressed after first line chemotherapy for epithelial ovarian, fallopian tube, or primary peritoneal cancer—Overall survival (OS) results. (2018) (8)
- Quality-of-life analysis of the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study comparing platinum-based versus non-platinum-based chemotherapy in patients with partially platinum-sensitive recurrent ovarian cancer (2018) (8)
- Correlation of Serum Cystatin C with Glomerular Filtration Rate in Patients Receiving Platinum-Based Chemotherapy (2016) (8)
- Fine‐needle cytology of metastatic endometrioid neoplasms: Experience with eight cases (2009) (7)
- Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician’s choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33) (2021) (7)
- Carboplatin (C) plus paclitaxel (P) versus carboplatin plus pegylated liposomal doxorubicin (PLD) in patients with advanced ovarian cancer (AOC): Final analysis of the MITO-2 randomized multicenter trial. (2010) (7)
- A randomized phase III study of gemcitabine (GEM) versus pegylated liposomal doxorubicin (PLD) in progressive/recurrent ovarian cancer (OC) (2007) (7)
- Clinical outcomes of metastatic renal carcinoma following disease progression to programmed death (PD)-1 or PD-L1 inhibitors (I-O): A Meet-URO group real-world study (Meet-Uro 7). (2020) (7)
- ENGOT-OV44/FIRST study: a randomized, double-blind, adaptive, phase III study of standard of care (SOC) platinum-based therapy ± dostarlimab followed by niraparib ± dostarlimab maintenance as first-line (1L) treatment of stage 3 or 4 ovarian cancer (OC). (2020) (7)
- Stage I juvenile granulosa cell tumors of the ovary: A multicentre analysis from the MITO-9 study. (2021) (7)
- Health-related quality of life in recurrent platinum-sensitive ovarian cancer-results from the CALYPSO trial. (2012) (7)
- Characteristics and outcome of BRCA mutated epithelial ovarian cancer patients in Italy: A retrospective multicenter study (MITO 21). (2021) (7)
- ROCSAN trial (GINECO-EN203b/ENGOT-EN8): A multicentric randomized phase II/III evaluating dostarlimab in combination with niraparib versus niraparib alone compared to chemotherapy in the treatment of endometrial/ovarian carcinosarcoma after at least one line of platinum based chemotherapy. (2021) (6)
- Medical treatment of resistant or recurrent epithelial ovarian cancer. (2006) (6)
- Plasma postheparin diamine oxidase in patients with small intestinal lymphoma (1991) (6)
- Joint ENGOT and GOG Foundation requirements for trials with industry partners (2019) (6)
- Predictive value of the Leuven HRD test compared with Myriad myChoice PLUS on 468 ovarian cancer samples from the PAOLA-1/ENGOT-ov25 trial (LBA 6) (2022) (6)
- Evaluation of Angiogenesis-Related Genes as Prognostic Biomarkers of Bevacizumab Treated Ovarian Cancer Patients: Results from the Phase IV MITO16A/ManGO OV-2 Translational Study (2021) (6)
- Management of ovarian cancer: guidelines of the Italian Medical Oncology Association (AIOM) (2020) (6)
- Complete resolution of psoriasis in a patient treated with stealth liposomal doxorubicin and carboplatin for ovarian cancer (2004) (6)
- Microsatellite Instability: From the Implementation of the Detection to a Prognostic and Predictive Role in Cancers (2022) (6)
- Transcatheter arterial procedures in the treatment of patients with hepatocellular carcinoma: a review of literature. (2003) (6)
- UNCOMMON TUMORS OF THE TESTIS (2014) (6)
- Maintenance olaparib plus bevacizumab (bev) after platinum-based chemotherapy plus bev in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): Efficacy by BRCA1 or BRCA2 mutation in the phase III PAOLA-1 trial. (2020) (6)
- Recurrent ovarian cancer in the era of poly-ADP ribose polymerase inhibitors: time to re-assess established clinical practices (2021) (6)
- In reply [8] (2005) (5)
- 892PTreatment beyond progression in patients with advanced RCC participating in the expanded access programme (EAP) (2017) (5)
- Bevacizumab As Maintenance Treatment in Patients With Ovarian Cancer: Wait for BRCA Testing. (2019) (5)
- Extending the platinum-free interval (PFI) with a non-platinum therapy in platinum (P)- sensitive recurrent ovarian cancer (OC): Results from the SOCRATES retrospective study (2006) (5)
- Patterns of progression and subsequent management of patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib versus placebo: the SOLO2/ENGOT Ov-21 trial (NCT01874353). (2020) (5)
- Costs of clinical trials with anticancer biological agents in an Oncologic Italian Cancer Center using the activity-based costing methodology (2019) (5)
- Efficacy and Safety of Mirvetuximab Soravtansine in Patients with Platinum-Resistant Ovarian Cancer with High Folate Receptor Alpha Expression: Results from the SORAYA Study (LBA 4) (2022) (5)
- Health-related quality of life (HRQoL) in advanced endometrial cancer (aEC) patients (pts) treated with lenvatinib plus pembrolizumab or treatment of physician’s choice (TPC). (2021) (5)
- 985TiPIMagyn050 / GOG3015 / ENGOT-ov39: A randomized, double-blind, phase III study of atezolizumab vs placebo combined with chemotherapy + bevacizumab in stage III-IV ovarian, fallopian tube & peritoneal cancers (OC) (2017) (5)
- Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trials. (2019) (4)
- Corrigendum: Pazopanib in Metastatic Renal Cancer: A “Real-World” Experience at National Cancer Institute “Fondazione G. Pascale” (2016) (4)
- Carboplatin plus paclitaxel versus carboplatin plus Stealth liposomal doxorubicin in patients with advanced ovarian cancer (AOC): Preliminary activity results of the MITO-2 randomized multicenter trial (2007) (4)
- Tamoxifen in hepatocellular carcinoma (1998) (4)
- Correction to: The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients with Cervical Cancer (2018) (4)
- Treatment of duodenal ulcers: An update (1993) (4)
- Role of adjuvant chemotherapy in early-stage endometrioid and clear-cell ovarian cancer. (2017) (4)
- Clinical outcome of renal cancer patients who early interrupted immunotherapy due to serious immune-related adverse events. Meet-Uro 13 trial on behalf of the MeetUro investigators (2021) (4)
- Renal cancer: Prognostic and predictive biomarkers (2015) (4)
- Acute Toxicity in Hypofractionated/Stereotactic Prostate Radiotherapy of Elderly Patients: Use of the Image-guided Radio Therapy (IGRT) Clarity System (2021) (4)
- Alienor/ENGOT-ov7 randomized trial exploring weekly paclitaxel (wP) + bevacizumab (bev) vs wP alone for patients with ovarian sex cord tumors (SCT) in relapse. (2018) (4)
- Carboplatin plus paclitaxel scheduling for advanced ovarian cancer - authors' reply. (2014) (4)
- Stop Flow in abdominal and pelvic cancer relapses. (2006) (4)
- Optimizing Management of Recurrent Epithelial Ovarian Cancer with Non–Platinum-Based Chemotherapy (2008) (4)
- 2639 Effectiveness and possible Molecular factors predictive of clinical Outcomes in patients with transitional cell carcinoma of the urothelial tract (TCCU) treated with VInfluninE: A multicenter retrospective study (MOVIE) of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) (2015) (4)
- From Clinical Trials to the Front Line: Vinflunine for Treatment of Urothelial Cell Carcinoma at the National Cancer Institute of Naples (2016) (4)
- A phase 2 single-arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pretreated with one immune checkpoint inhibitor: The BREAKPOINT trial (MeetUro trial 03-NCT03463681). (2021) (4)
- Joint ENGOT and GOG Foundation requirements for trials with industry partners. (2019) (4)
- Clinical Outcomes of Metastatic Renal Carcinoma Following Disease Progression to Programmed Death (PD)-1 or PD-L1 Inhibitors (IO) (2021) (4)
- The clinical and translational research activities at the INT – IRCCS “Fondazione Pascale” cancer center (Naples, Italy) during the COVID-19 pandemic (2020) (4)
- Surveillance in stage I MOGCTs (malignant ovarian germ cell tumors): A MITO prospective study (multicenter Italian trials in ovarian cancer). (2019) (4)
- Cytoreductive Surgery for Heavily Pre-Treated, Platinum-Resistant Epithelial Ovarian Carcinoma: A Two-Center Retrospective Experience (2020) (4)
- Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 Trial (2023) (4)
- A Phase I Study of Paclitaxel and Epirubicin, without and with Filgrastim, for the Treatment of Platinum-Resistant Advanced Ovarian Cancer (1999) (4)
- Expression III: What do primary and recurrent ovarian cancer (OC) patients expect from their doctors and therapy management? Results of a survey in eight European countries with 1,743 patients (NOGGO/ENGOT-OV9 study). (2013) (4)
- Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study (2023) (3)
- Phase III PAOLA-1/ENGOT-ov25 trial: olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer treated with platinum-based chemotherapy plus bevacizumab (2019) (3)
- Impact of COVID-19 on medical treatment patterns in gynecologic oncology: a MITO group survey (2021) (3)
- Efficacy and safety of front-line bevacizumab (BEV), weekly paclitaxel (wPAC), and q3w carboplatin (C) in elderly patients (pts) with ovarian cancer (OC): Subgroup analysis of OCTAVIA. (2013) (3)
- Cytoreductive surgery followed by chemotherapy and olaparib maintenance in BRCA 1/2 mutated recurrent ovarian cancer: a retrospective MITO group study (2021) (3)
- Topotecan compared with no terapy and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study (2004) (3)
- Immunotherapy Bridge 2016 and Melanoma Bridge 2016: meeting abstracts (2017) (3)
- Targeting immunometabolism mediated by the IDO1 Pathway: A new mechanism of immune resistance in endometrial cancer (2022) (3)
- BRCA1/2 Molecular Assay for Ovarian Cancer Patients: A Survey through Italian Departments of Oncology and Molecular and Genomic Diagnostic Laboratories (2019) (3)
- Randomized phase II study of niraparib plus best supportive care (BSC) versus BSC alone as maintenance treatment in patients with advanced urothelial carcinoma (UC) whose disease did not progress after first-line platinum-based chemotherapy (PBCT): The Meet-URO12 trial. (2022) (3)
- Surveillance alone in stage I malignant ovarian germ cell tumors: a MITO (Multicenter Italian Trials in Ovarian cancer) prospective observational study (2021) (3)
- A phase II open-label study of cabozantinib after first-line treatment including an immune-checkpoint combination in patients with advanced or unresectable renal cell carcinoma: The BREAKPOINT trial (MeetUro trial 03 - EudraCT number 2018-000582-36). (2021) (3)
- Real-world experience with trabectedin for the treatment of recurrent ovarian cancer (2021) (3)
- KEYNOTE-C93/GOG-3064/ENGOT-en15: A phase 3, randomized, open-label study of first-line pembrolizumab versus platinum-doublet chemotherapy in mismatch repair deficient advanced or recurrent endometrial carcinoma. (2022) (3)
- 8002 ORAL Front-line Bevacizumab (BEV) Combined With Weekly Paclitaxel (wPAC) and Carboplatin (C) for Ovarian Cancer (OC): Safety Results From the Concurrent Chemotherapy (CT) Phase of the OCTAVIa Study (2011) (3)
- European Network of Gynaecological Oncological Trial Groups’ requirements for trials between academic groups and industry partners – a new Model D for drug and medical device development (2020) (3)
- A fully virtual and nationwide molecular tumor board for gynecologic cancer patients: the virtual experience of the MITO cooperative group (2022) (3)
- Phase II prospective study on trabectedin (T) in BRCA-mutated and BRCAness phenotype advanced ovarian cancer (AOC) patients (pts): The MITO 15 trial. (2014) (3)
- Residual neurotoxicity in patients with ovarian cancer in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: The Multicenter Italian Trials in Ovarian cancer (MITO-4) retrospective study (2005) (3)
- Impact of previous nephrectomy on clinical outcome of metastatic renal carcinoma treated with immune-oncology (I-O):A real-world study on behalf of Meet-URO group (MeetUro-7b). (2020) (3)
- Characterization of 2 novel and 2 recurring BRCA1 germline mutations in breast and/or ovarian carcinoma patients from the area of Naples. (2002) (3)
- Multidisciplinary treatment of early stage endometrial cancer. (2013) (3)
- 843P Association of gene expression signatures and TMB with response to pembrolizumab (pembro) in patients (pts) with recurrent ovarian cancer (ROC) enrolled in KEYNOTE-100 (2020) (3)
- Immunotherapy and Sonpavde score validation in advanced upper tract urothelial carcinoma: a retrospective study by the Italian Network for Research in Urologic-Oncology. (2021) (3)
- Stop Flow in Abdominal and Pelvic Relapses. Phase I Study and Phase Ii Preliminary. Sitilo National Project Data (2002) (3)
- Prognostic Evidence of the miRNA-Based Ovarian Cancer Signature MiROvaR in Independent Datasets (2021) (3)
- Baseline quality of life (QOL) as a predictor of stopping chemotherapy early, and of overall survival, in platinum-resistant/refractory ovarian cancer (PRROC): The GCIG symptom benefit study (SBS). (2016) (2)
- 2022-RA-873-ESGO Validation study of the ‘NOGGO-GIS ASSAY’ based on ovarian cancer samples from the first-line PAOLA-1/ENGOT-ov25 phase-III trial (2022) (2)
- Arthralgia in patients with ovarian cancer treated with bevacizumab and chemotherapy (2020) (2)
- D01*MITO (Multicentre Italian Trials in Ovarian cancer) - CERV 2 trial: a randomized phase II study of carboplatin and paclitaxel +/- cetuximab, in advanced and/or recurrent cervical cancer (2015) (2)
- Validation of MiROvaR, a microRNA-based predictor of early relapse in early stage epithelial ovarian cancer as a new strategy to optimise patients' prognostic assessment. (2021) (2)
- Phase II study on pemetrexed in advanced and/or recurrent cervical cancer patients: a MITO study (2008) (2)
- A multicentre phase 2 study of carboplatin (C) plus pegylated liposomal doxorubicin (PLD) as first-line chemotherapy for patients (pts) with advanced or recurrent endometrial carcinoma (AEC): The END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer) Group. (2006) (2)
- From clinical trials to clinical use of checkpoint inhibitors for patients with metastatic urothelial cancer. (2020) (2)
- Biological Role of Tumor/Stromal CXCR4-CXCL12-CXCR7 in MITO16A/MaNGO-OV2 Advanced Ovarian Cancer Patients (2022) (2)
- 199 Randomised Phase II BGOG/ENGOT-cx1 study of paclitaxel-carboplatin with or without nintedanib in first-line recurrent or advanced cervical cancer (2021) (2)
- Maintenance olaparib in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) by somatic (s) or germline (g) BRCA and other homologous recombination repair (HRR) gene mutation status: Overall survival (OS) results from the ORZORA study. (2022) (2)
- Olaparib beyond progression compared with platinum chemotherapy after secondary cytoreductive surgery in patients with recurrent ovarian cancer: phase III randomized, open-label MITO 35b study, a project of the MITO-MANGO groups (2022) (2)
- ORZORA: Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status (2021) (2)
- Health-related quality of life (HRQL) and progression-free survival (PFS) in patients with recurrent ovarian cancer: Results from the CALYPSO trial. (2010) (2)
- Mathematical modeling of CA125 kinetics in recurrent ovarian cancer (ROC) patients treated with chemotherapy and predictive value of early modeled kinetic parameters in CALYPSO trial: A GCIG study. (2011) (2)
- Chemotherapy-free treatments: are we ready for prime time? (2019) (2)
- Analysis of A Disintegrin and Metalloprotease 17 (ADAM17) Expression as a Prognostic Marker in Ovarian Cancer Patients Undergoing First-Line Treatment Plus Bevacizumab (2022) (2)
- Phase I study of carboplatin, cisplatin, and cyclophosphamide without and with lenograstim for the treatment of ovarian cancer. (1997) (2)
- A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial (Meet-Uro trial 03) (2022) (2)
- An Italian National Survey on Ovarian Cancer Treatment at first diagnosis. There's None so Deaf as those who will not Hear (2021) (2)
- LIO-1: Initial phase 2 experience of lucitanib + nivolumab in patients with metastatic or recurrent cervical cancer (NCT04042116; ENGOT-GYN3/AGO/LIO) (034) (2022) (2)
- Endometrial carcinosarcoma (2022) (2)
- 885TiP LIO-1: A phase II study of lucitanib + nivolumab in patients (pts) with gynaecological tumours (CO-3810-101; NCT04042116; ENGOT-GYN3/AGO/LIO) (2020) (2)
- Emesis and nausea related to single agent trabectedin in ovarian cancer patients: a sub-study of the MITO15 project (2017) (2)
- Carboplatin plus paclitaxel versus carboplatin plus stealth liposomal doxorubicin in patients with advanced ovarian cancer (AOC): Final results of the MITO-2 randomized multicenter trial. (2009) (2)
- F03*Effectiveness and possible molecular factors predictive of clinical outcomes in patients with transitional cell carcinoma of the urothelial tract (TCCU) treated with VInfluninE: a multicenter retrospective study (MOVIE) of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) (2015) (2)
- Clinical characteristics and molecular aspects of low-grade serous ovarian and peritoneal cancer: a multicenter, observational, retrospective analysis of MITO Group (MITO 22) (2022) (2)
- Trabectedin plus pegylated liposomal doxorubicin (PLD) in patients with platinum-sensitive recurrent ovarian cancer (PSROC) regardless of prior use of antiangiogenics: First results of an observational, prospective study. (2018) (2)
- Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21) (2021) (2)
- ENGOT-EN9/LEAP-001: A phase III, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer (2019) (2)
- O013/#573 Tisotumab vedotin (TV) + bevacizumab or pembrolizumab or carboplatin in recurrent/metastatic cervical cancer (R/MCC): phase 1B/2 engot-CX8/GOG-3024/innovaTV 205 study dose-escalation results (2021) (2)
- A deep learning solution for detection of homologous recombination deficiency in ovarian cancer using low pass whole-genome sequencing: Evaluation of the analytical performance. (2022) (2)
- Association of BRCA1/2, homologous recombination deficiency, and PD-L1 with clinical outcomes in patients receiving atezolizumab versus placebo combined with carboplatin, paclitaxel, and bevacizumab for newly diagnosed ovarian cancer: exploratory analyses of IMagyn050/GOG3015/ENGOT-ov39 (2021) (2)
- Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1st–2nd, 2021 (2022) (2)
- Management of Metastatic Endometrial Cancer: Physicians’ Choices Beyond the First Line. A MITO Survey (2022) (2)
- Postheparin plasma diamine oxidase in subjects with celiac disease. (1991) (2)
- Cell kinetics and polyamine enzymes in the intestinal mucosa of rats with azoxymethane induced tumours. (1994) (2)
- 886PDTRABECTEDIN IN PATIENTS WITH BRCA MUTATED AND BRCANESS PHENOTYPE ADVANCED OVARIAN CANCER (AOC): PHASE II PROSPECTIVE MITO-15 STUDY. (2014) (1)
- 837PPOOR RISK METASTATIC RENAL CELL CARCINOMA (MRCC) PATIENTS ARE NOT A HOMOGENEOUS GROUP: A NEW STRATIFICATING MODEL IN THE ERA OF TARGETED THERAPY. (2014) (1)
- Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial. (2023) (1)
- How to sequence treatment in relapsed ovarian cancer. (2020) (1)
- 800TiP Meet-URO 12: A randomized phase II trial of niraparib versus best supportive care (BSC) as maintenance treatment in patients with locally advanced or metastatic urothelial cancer (UC) whose disease did not progress after completion of first-line platinum-based chemotherapy (2020) (1)
- Number Needed to Treat in Trials of Targeted Therapies for Advanced Ovarian Cancer (2022) (1)
- O028/#376 Clinical benefit of mirvetuximab soravtansine in ovarian cancer patients with high folate receptor alpha expression: results from the soraya study (2022) (1)
- Very early PSA response to abiraterone in mCRPC patients: A novel prognostic factor to predict overall survival. (2016) (1)
- Effect of gender on the outcome of patients receiving nivolumab for metastatic renal cancer: Results from a large study population. (2019) (1)
- A multicenter, retrospective study on impact of immunotherapy in urothelial carcinoma with bone metastases (Meet-Uro01 Study). (2021) (1)
- 254TiP ENGOT-cx11/KEYNOTE-A18: A phase III, randomized, double-blind study of pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer (2020) (1)
- Oligometastatic prostate cancer treatment. (2021) (1)
- The European Network for Gynaecological Oncological Trial Groups Charta for Privileged Partnership (2015) (1)
- Chemotherapy-free treatments: are we ready for prime time? (2019) (1)
- Thromboembolic events and antithrombotic prophylaxis in advanced ovarian cancer patients treated with bevacizumab: secondary analysis of the phase IV MITO-16A/MaNGO-OV2A trial (2021) (1)
- Sequencing chemotherapy and immune checkpoint inhibitors (ICI) in metastatic urothelial carcinoma (UC): Meet-Uro1 study. (2019) (1)
- Palbociclib versus placebo in combination with letrozole for patients with advanced or recurrent endometrial cancer: The NSGO ENGOT-EN3/PALEO trial. (2017) (1)
- Evolution of the Ovarian Cancer Treatment Paradigm, Including Maintenance Treatment, in the US and Europe: A Real-World Chart Review Analysis (2017-2020) (028) (2022) (1)
- 0755: Practice Patterns of Radiotherapy in Endometrial Cancer Among Member Groups of the Gynecologic Cancer Intergroup (Gcig) (2006) (1)
- Expression III: Final results of an international survey in eight European countries with 1,830 patients—What are the differences in expectations from their doctors and therapy management of patients with primary and recurrent ovarian cancer? (NOGGO/ENGOT-ov4 study). (2014) (1)
- Response to the Letter to the Editor by Lockley et al. commenting on 'Can we replace adjuvant chemotherapy with surveillance for stage IA-C immature ovarian teratomas of any grade? an international multicenter analysis'. (2021) (1)
- Correction to: Correction to: The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients with Cervical Cancer (2018) (1)
- Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1st–2nd, 2021 (2022) (1)
- PARPi related toxicities: do we need more appropriate instruments to evaluate it? (2018) (1)
- 935PDBRCA1&2 tumoral and germline status for ovarian cancer patients in first line setting within the PAOLA-01 trial (2017) (1)
- MEK inhibitor as single agent in low grade serous ovarian and peritoneal cancer: a systematic review and meta-analysis. (2022) (1)
- [Usefulness of ultrasonography in the study of superficial lymph nodes. A case of cat scratch disease]. (2002) (1)
- O002/#43 Randomized phase 3 study of lenvatinib plus pembrolizumab for advanced endometrial cancer (aec): subgroup analysis of patients with DNA mismatch repair deficient (DMMR) tumors (2021) (1)
- Reirradiation of Locally Recurrent Prostate Cancer with Cyberknife® System or Volumetric Modulated Arc Therapy (VMAT) and IGRT-Clarity®: Outcomes, Toxicities and Dosimetric Evaluation (2022) (1)
- A randomized, double-blind, placebo-controlled, phase II study to assess the efficacy and safety of farletuzumab (MORAb-003) in combination with carboplatin plus either paclitaxel or pegylated liposomal doxorubicin (PLD) in subjects with low CA125 platinum-sensitive ovarian cancer. (2016) (1)
- How to Design Clinical Trials (2016) (1)
- Cabozantinib (Cabo) beyond progression improves survival in advanced renal cell carcinoma patients: The CABEYOND study (Meet-Uro 21). (2021) (1)
- 959 Expression of functional CXCR4 on colorectal human cancer (2003) (1)
- Concomitant medication of cetirizine in advanced melanoma could enhance anti-PD-1 efficacy by promoting M1 macrophages polarization (2022) (1)
- Basal NK activity and early Treg function inhibition predicts Nivolumab responsiveness in metastatic renal cancer patients (REVOLUTION) trial (2019) (1)
- Efficacy and safety of trabectedin for the treatment of advanced uterine or ovarian carcinosarcoma: Results of a phase II multicenter clinical trial (MITO-26). (2022) (1)
- Cytological diagnosis of Xp11 translocation renal cell carcinoma: An unusual suspect in bone metastases from unknown primary malignancies (2020) (1)
- MITO (Multicentre Italian Trials in Ovarian cancer): CERV 2 trial—A randomized phase II study of carboplatin and paclitaxel +/- cetuximab, in advanced and/or recurrent cervical cancer. (2015) (1)
- A novel oncologist-led BRCA1/2 germline mutation (gBRCAm) testing and counselling model for patients with ovarian cancer: Interim results from the ENGAGE (NCT02406235) study (2016) (1)
- Thinking twice before abandoning first-line chemotherapy in ovarian cancer: report of two cases and literature review. Passing from tri-weekly to weekly regimens (2012) (1)
- 0009: Extending the Platinum-Free Interval (PFI) with a Non-Platinum Therapy in Platinum (P)-Sensitive Recurrent Ovarian Cancer (Oc): Results From the Socrates Retrospective Study (2006) (1)
- Carboplatin, cisplatin and paclitaxel in the treatment of patients with epithelial ovarian cancer. (2000) (1)
- Gestational choriocarcinoma with residual lung tumor after completing treatment: a case report (2021) (1)
- A miRNA signature assessing ovarian cancer prognosis (2016) (1)
- What have we learned from immunotherapy? Report from the 3rd and 4th meetings of the Campania Society of Oncology Immunotherapy (SCITO) (2016) (1)
- Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): Results from a subgroup of patient from the MITO-16A-MANGO OV2A phase 4 trial. (2015) (1)
- Evaluation of perioperative management of advanced ovarian (tubal/peritoneal) cancer patients: a survey from MITO-MaNGO Groups (2021) (1)
- Urotensin II receptor determines prognosis of bladder cancer regulating cell motility/invasion (2014) (1)
- Adjuvant treatment of high-risk renal cell carcinoma: the jury is still out. (2018) (0)
- Corrigendum to 'The forefront of ovarian cancer therapy: update on PARP inhibitors': [Annals of Oncology 31 (2020) 1148-1159]. (2021) (0)
- Neutrophil-to-lymphocyte ratio predicts platinum sensitivity in epithelial ovarian cancer patients: A MITO24 retrospective study (2019) (0)
- TAMOXIFEN IN HEPATOCELLULAR CARCINOMA. AUTHORS' REPLY (1998) (0)
- Ovarian Sertoli-Leyding cell tumors (OSLT). A retrospective MITO study (2011) (0)
- 8104 POSTER Expanding the role of the clinical research nurse in an Italian cooperative oncology research group (2007) (0)
- II Line Trans-catheter Arterial Treatment with 5-fluorouracil, Leucovorin, Epidoxorubicine and Carboplatin (Flec) in Locally Advanced Pancreatic Adenocarcinoma Our Experience (2002) (0)
- Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge”, Napoli, November 30th 2016 (2017) (0)
- Bevacizumab as first-line treatment of ovarian cancer: strengths and weaknesses of subgroup analyses (2016) (0)
- TCRM-4317-Treatment of recurrent epithelial ovarian cancer (2009) (0)
- Cx. Incorporation of ctDNA analysis into routine follow-up for early detection of relapse may allow earlier initiation of alternate treatment modalities. Legal entity responsible for the study: The National Committee on Health Research (2019) (0)
- Corrigendum to “Pegylated liposomal doxorubicin combined with carboplatin: A rational treatment choice for advanced ovarian cancer” [Crit. Rev. Oncol./Hematol. 73 (2010) 23–30] (2010) (0)
- Immunotherapy Bridge 2016 and Melanoma Bridge 2016: meeting abstracts (2017) (0)
- Expression of Insulin-like Growth Factor (IGF)-Il and IGF-I Receptor during Proliferation and Differentiation of (1994) (0)
- ENGOT-en9/LEAP-001: A phase III, randomized, active-controlled, open-label study of pembrolizumab plus lenvatinib versus paclitaxel plus carboplatin for newly diagnosed advanced or recurrent endometrial cancer (2020) (0)
- 2022-RA-883-ESGO Rare Cancers in Gynecologic Oncology, ENGOT initiative for a European Registry (2022) (0)
- 0016: Practice Patterns of Radiotherapy in Cervix Cancer Among Member Groups of the Gynecologic Cancer Intergroup (GCIG) (2006) (0)
- Clinical Trials with Pegylated Liposomal Doxorubicin in (2013) (0)
- Having progress with upfront chemotherapy in ovarian cancer. Is it still a possible goal? (2010) (0)
- Subject Index, Vol. 46, Supplement 2, 1990 (1990) (0)
- Myoid gonadal stromal tumor, a case report with review of the literature (2022) (0)
- The clinical and translational research activities at the INT – IRCCS “Fondazione Pascale” cancer center (Naples, Italy) during the COVID-19 pandemic (2020) (0)
- The way to precision medicine in gynecologic cancers: The first case report of an exceptional response to alpelisib in a PIK3CA-mutated endometrial cancer (2023) (0)
- Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma (2022) (0)
- Molecular prognostic and predictive markers in gynecologic cancers: The translational 1 (T-1) study of the Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies (MITO) group. (2010) (0)
- A randomized, double-blind, placebo-controlled, phase II study to assess the efficacy/safety of farletuzumab in combination with carboplatin plus paclitaxel or carboplatin plus pegylated liposomal doxorubicin (PLD) in women with low CA-125 platinum-sensit (2021) (0)
- Effect of systemic therapies or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The Meet‐Uro 19BEYOND study (2022) (0)
- Ki67 as a Predictor of Response to PARP Inhibitors in Platinum Sensitive BRCA Wild Type Ovarian Cancer: The MITO 37 Retrospective Study (2023) (0)
- Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer. (2023) (0)
- The Clinical and Translational Research Activities at the INT – IRCCS “Fondazione Pascale” Center (Naples, Italy) during the COVID-19 Pandemic (2020) (0)
- Clinical outcomes of volume of disease on patients receiving enzalutamide versus abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer (2023) (0)
- Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge”, Napoli, December 5th 2015 (2016) (0)
- TP034/#1534 Randomized phase III trial on niraparib-TSR-042 (Dostarlimab) versus physician’s choice chemotherapy in recurrent ovarian, fallopian tube, primary peritoneal cancer platinum resistant patients: nitche trial(MITO 33) (2022) (0)
- Mutated Von Hippel-Lindau-renal cell carcinoma (RCC) promotes patients specific natural killer (NK) cytotoxicity (2018) (0)
- 164 ENGOT-cx11/GOG 3047/KEYNOTE-A18: a phase 3, randomized, double-blind study of pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer (2020) (0)
- 897PEfficacy and safety data in elderly patients (pts) with metastatic renal cell carcinoma (mRCC) included in the nivolumab expanded access program (EAP) in Italy (2017) (0)
- Vol. 56, 1999 (1999) (0)
- First-Line Systemic Therapy (Chemo/Antiangiogenics) (2017) (0)
- D02Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): results from a subgroup of patient from the MITO-16A-MANGO OV2A phase 4 trial (2015) (0)
- Villous adenoma of the rectum associated with malabsorption. (1991) (0)
- G04Quality of life (QOL) analysis of the MITO8 phase 3 trial, a collaboration of MITO, Mango, AGO Study Group, BGOG, ENGOT, and GCIG (2016) (0)
- Management of Metastatic Disease in Campania (MAMETIC): An Observational Multicenter Retrospective and Prospective Trial on Palliative Radiotherapy in an Italian Region. Study Protocol (2022) (0)
- Management of Metastatic Disease in Campania (MAMETIC): Epidemiologic Data and Palliative Radiotherapy in an Italian Region. Study Protocol (2021) (0)
- “Intestinal-Type” Vulvar Adenocarcinoma: A Review of the MITO Rare Tumors Group (2022) (0)
- Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer (2023) (0)
- Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors (2023) (0)
- 2022-RA-1623-ESGO Effect of bevacizumab and complete cytoreductive surgery in advanced low grade serous ovarian cancer: a secondary analysis of MITO 22 (2022) (0)
- Faculty Opinions recommendation of Conservative management of early-stage epithelial ovarian cancer: results of a large retrospective series. (2013) (0)
- Immunotherapy may protect cancer patients from SARS-CoV-2 infection: a single-center retrospective analysis (2021) (0)
- C24Prognostic assessment in Abiraterone Acetate (AA) post-Docetxel (DOC) mCRPC cohort (2016) (0)
- EPV036/#142 European network for gynaecological oncological trial (ENGOT)-CX11/gynecologic oncology group (GOG) 3047/keynote-A18: phase 3 trial of pembrolizumab plus chemoradiotherapy in high-risk locally advanced cervical cancer (2021) (0)
- Aortic stenosis and ACE inhibitors (1998) (0)
- Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial (2023) (0)
- Nivolumab serum concentration in metastatic melanoma patients could be related to outcome and enhanced immune activity: a gene profiling retrospective analysis (2022) (0)
- Aortic stenosis and ACE inhibitors (1998) (0)
- 933 A large, multicenter, retrospective study on efficacy and safety of stereotactic body radiotherapy in oligometastatic cervical cancer (MITO-RT2/RAD) (2021) (0)
- Sunitinib in advanced clear cell renal cancer: A single centre experience (2008) (0)
- Changing paradigm in recurrent ovarian cancer treatment (2017) (0)
- Abstract 5702: Ovarian cancer tumor microenvironment and atezolizumab (atezo) clinical activity: IMagyn050 sub-study (2023) (0)
- Granulosa cell tumors (GCTs) of the ovary: What is the role of radiotherapy? (2022) (0)
- Progression free survival (PFS) as a surrogate endpoint for overall survival (OS) in first-line advanced ovarian cancer (AOC) therapy: A Gynecologic Cancer InterGroup individual (GCIG) patient-level (IPD) analysis of multiple randomized trials. (2018) (0)
- 2022-RA-324-ESGO Phase 2 results from the LIO-1 STUDY (NCT04042116; ENGOT-GYN3/AGO/LIO): efficacy and safety of lucitanib + nivolumab in patients with advanced gynaecological malignancies (2022) (0)
- Efficacy of Immunotherapy in Advanced Renal Cell Carcinoma (RCC) Patients Despite the Early Treatment Interruption Due to Serious Immune-related Adverse Events. Meet-Uro 13 Trial on Behalf of the MeetUro Investigators (2021) (0)
- Role and relevance of quality indicators in the selection of first-line treatment of patients with metastatic renal cell carcinoma: a position paper of the MeetURO Group. (2019) (0)
- Abstract 580: Nivolumab treatment of metastatic renal cancer patients impairs Tregs and potentiates NK function: The role of CXCR4 inhibition (“REVOLUTION Trial”) (2017) (0)
- Health-Related Quality of Life in Patients With Advanced Endometrial Cancer Treated With Lenvatinib Plus Pembrolizumab or Treatment of Physician's Choice. (2023) (0)
- 19 A large, multicenter, retrospective study on efficacy and safety of stereotactic body radiotherapy (SBRT) in oligometastatic ovarian cancer (MITO RT1 study) (2019) (0)
- Pembrolizumab as a single agent for patients with MSI-H advanced endometrial carcinoma (2022) (0)
- 2022-RA-913-ESGO Clinical performance evaluation of a novel deep learning solution for homologous recombination deficiency detection (2022) (0)
- 776 Role of optimal cytoreduction in advanced stage malignant ovarian germ cell tumors, data from the MITO-9 trial (2021) (0)
- Single Agents or Combination Chemotherapy for Advanced Ovarian Carcinoma in Elderly Patients: Pro Single Agents (2002) (0)
- Prognostic Value of Serum Biological Markers in Patients with Hepatocellular Carcinoma 1 (2001) (0)
- [Evolution of the treatment of locoregional recurrences of gastric carcinoma]. (2005) (0)
- TP033/#1441 MITO 25.1: a randomized, molecular driven phase II trial of carboplatin-paclitaxel-bevacizumab vs carboplatin-paclitaxel-bevacizumab-rucaparib vs carboplatin-paclitaxel-rucaparib, selected according to HRD status, in patients with advanced ovarian cancer (2022) (0)
- 739P Impact of previous nephrectomy on clinical outcome of metastatic renal carcinoma treated with immuno-oncology: A real-world study on behalf of Meet-URO group (MeetUro-7b) (2020) (0)
- How long have we got? The accuracy of physicians’ estimates and scenarios for survival time in 898 women with recurrent ovarian cancer (ROC). (2019) (0)
- Corrigendum: Pazopanib in Metastatic Renal Cancer: A "Real-World" Experience at National Cancer Institute "Fondazione G. Pascale". (2016) (0)
- Subject Index Vol. 56, 1999 (1999) (0)
- Prescribing pattern of anticoagulants in patients with cancer associated thrombosis: Results of a survey among MITO group and AIOM society. (2023) (0)
- 2022-RA-1392-ESGO Tisotumab vedotin combinations with pembrolizumab or carboplatin in patients with recurrent/metastatic cervical cancer: interim results of ENGOT Cx8/GOG-3024/innovaTV205 (2022) (0)
- P118 European, non-interventional, phase IV NIMES-ROC trial of trabectedin plus pegylated liposomal doxorubicin in patients with platinum-sensitive recurrent ovarian cancer: an interim analysis (2019) (0)
- Are adverse events (AEs) predictive of nivolumab activity? Data from the Italian expanded access program in metastatic renal cell carcinoma (mRCC). (2018) (0)
- Efficacy of next line of therapy after treatment with lenvatinib (LEN) in combination with pembrolizumab (pembro) versus treatment of physician’s choice (TPC) in patients (pts) with advanced endometrial cancer (aEC): Exploratory analysis of Study 309/KEYNOTE-775. (2022) (0)
- New approach to implement cancer patient care: The valutazione percorso rete oncologica campana (ValPeROC)-experience from an Italian oncology network. (2022) (0)
- The role of immunotherapy in solid tumors: report from the Campania Society of Oncology Immunotherapy (SCITO) meeting, Naples 2014 (2014) (0)
- 261 ENGOT-cx11/GOG 3047/KEYNOTE-A18: phase 3 randomized study of pembrolizumab + chemoradiotherapy for high-risk locally advanced cervical cancer (2021) (0)
- Contents Vol. 71, 2006 (2007) (0)
- Subject Index Vol. 71, 2006 (2007) (0)
- Putrescine uptake and cell growth induced by pentagastrin and epidermal growth factor in human colon cancer cells (1990) (0)
- Ovarian cancer in older women (2006) (0)
- Clinical outcome of renal cancer patients who early interrupted immunotherapy due to serious immune-related adverse events. Meet-Uro 13 trial on behalf of the MeetUro investigators (2021) (0)
- First-Line Chemotherapy With Fluorouracil and Folinic Acid for Advanced Colorectal Cancer in Elderly Patients (2003) (0)
- Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: Outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status in the ORZORA trial. (2023) (0)
- Chemotherapy in the adjuvant and advanced-recurrent settings (2013) (0)
- POSITRON EMISSION TOMOGRAPHY WITH FDG (PET-FDG) IN RECURRENT EPITHELIAL OVARIAN CANCER (EOC): RADIOLOGIC-SURGICAL CORRELATIONS (2004) (0)
- A loss of microRNA expression as a characterization of synchronous peritoneal secondary localizations of epithelial ovarian cancer as compared to primary tumors. (2013) (0)
- I293 A CONCLUSIVE WORD ON THE ROLE OF CHEMOTHERAPIES IN GYNECOLOGIC MALIGNANCIES (2012) (0)
- Ovarian Cancer Radiosensitivity: What Have We Understood So Far? (2022) (0)
- ENGAGE: Evaluation of a streamlined oncologist-led BRCA mutation (BRCAm) testing and counselling model for patients with ovarian cancer. (2017) (0)
- 2022-RA-1540-ESGO MITO 25.1: a randomized, molecular driven phase II trial of carboplatin-paclitaxel-bevacizumab vs carboplatin-paclitaxel-bevacizumab-rucaparib vs carboplatin-paclitaxel-rucaparib, selected according to HRD status, in patients with advanced (Stage III B-C-IV) ovarian, primary perito (2022) (0)
- (Anticancer Research 32, 5 (1889)) (2012) (0)
- TP016/#1442 Keynote-C93/GOG-3064/ENGOT-EN15: phase 3, randomized, open-label study of first-line pembrolizumab versus platinum-doublet chemotherapy in mismatch repair deficient advanced or recurrent endometrial carcinoma (2022) (0)
- Fine-Needle Cytology of Metastatic Endometrioid Neoplasms: With Eight Cases (2009) (0)
- Prognostic role of T3/T4 ratio in metastatic renal cell carcinoma (mRCC): Preliminary results of the threeFOUR multicenter study (Meet-Uro 14). (2020) (0)
- Contents Vol. 86, 2014 (2014) (0)
- Neoplastic disease in fertile age: Psychological support during the course of the mother-child experience. (2004) (0)
- Biological and clinical impact of membrane EGFR expression in a subgroup of OC patients from the phase IV ovarian cancer MITO-16A/MANGO-OV2A trial (2023) (0)
- 2022-RA-723-ESGO Hormone replacement therapy in gynecological cancer survivors and BRCA mutation carriers: a MITO group survey (2022) (0)
- Anticancer Research (2012) 30, 11 (4633) (2012) (0)
- Effect of bevacizumab in advanced low grade serous ovarian cancer: Data from the MITO 22 trial. (2023) (0)
- Role of AR-V7 and AR-FL in resistance to hormonal therapy in mCRPC: Independent actors or reciprocal drivers? A translational study by Meet-Uro group. (2018) (0)
- Assessment of prognostic factors in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (AA) after docetaxel (DOC). (2016) (0)
- Vulvar Paget’s Disease: A Systematic Review of the MITO Rare Cancer Group (2023) (0)
- Nivolumab-ipilimumab in renal cell carcinoma metastatic to the bones: A case report. (2022) (0)
- Abstract 6675: Basal NK activity and early Tregs inhibition predicts nivolumab responsiveness in metastatic renal cancer patients (REVOLUTION) trial (2020) (0)
- The European Network of Gynecological Oncological Trial Groups (2012) (0)
- 2022-RA-1433-ESGO Reproductive outcomes after conservative treatment in malignant ovarian germ cell tumors (MOGCTs) patients: a MITO-9 study (2022) (0)
- MITO END-3: A Randomized Phase II Trial of Avelumab Plus Carboplatin and Paclitaxel Compared to Carboplatin and Paclitaxel in Advanced or Recurrent Endometrial Cancer (2022) (0)
- VEGF inhibitors: a new era in the treatment of metastatic ovarian cancer (2013) (0)
- Tamoxifen in the treatment of recurrent, advanced border line ovarian cancer: A single centre experience (2008) (0)
- Abstract 426: Targeting CXCR4 reduced T regulatory cells (Tregs) -mediated cell proliferation suppression in renal cell carcinoma (RCC) patients (2015) (0)
- Addition of Niraparib to Best Supportive Care as Maintenance Treatment in Patients with Advanced Urothelial Carcinoma Whose Disease Did Not Progress After First-line Platinum-based Chemotherapy: The Meet-URO12 Randomized Phase 2 Trial. (2022) (0)
- 23 Impact of COVID-19 in gynecologic oncology: a nationwide Italian survey (2020) (0)
- Docetaxel and zoledronic acid combination administered in two different sequences in hormone refractory prostate cancer patients: Phase I clinical study – ZANTE (2008) (0)
- C14Retrospective observational study of Vinflunine (VFL) in patients (pts) with transitional cell carcinoma of the urothelial tract (TCCU): final results of a real world population study (MOVIE-GOIRC01/2014 trial) (2016) (0)
- Progression free survival as a surrogate endpoint for overall survival in first-line therapy of advanced ovarian cancer: A Gynecologic Cancer InterGroup (GCIG) individual patient-level meta-analysis (2018) (0)
- Active therapy or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The BEYOND study (Meet-Uro 19). (2021) (0)
- 2022-RA-1638-ESGO Randomized phase III trial on Niraparib-TSR-042 (dostarlimab) versus physician’s choice in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33) (2022) (0)
- A randomized, double-blind, placebo-controlled, phase II study to assess the efficacy/safety of farletuzumab in combination with carboplatin plus paclitaxel or carboplatin plus pegylated liposomal doxorubicin (PLD) in women with low CA-125 platinum-sensitive ovarian cancer (2021) (0)
- Effect of gastrin and pentagastrin on CaCo-2 colon carcinoma cells (1990) (0)
- 323 ENGOT-en9/LEAP-001: a phase 3 study of first-line pembrolizumab plus lenvatinib compared with chemotherapy in advanced or recurrent endometrial cancer (2020) (0)
- miRNA-based signature for predicting epithelial ovarian cancer recurrence (2017) (0)
- Baseline predictors of early treatment failure in patients with platinum resistant/refractory (PRR) and potentially platinum sensitive (PPS ≥ 3) recurrent ovarian cancer (ROC) receiving ≥ 3 lines of chemotherapy: The Gynaecologic Cancer Intergroup (GCIG) Symptom Benefit Study (SBS). (2015) (0)
- Real-life clinical practice results with vinflunine in patients with relapsed platinum-treated metastatic urothelial carcinoma: an Italian multicenter study (MOVIE-GOIRC 01–2014) (2017) (0)
- EP064/#192 Potential mechanism for ocular adverse events observed with tisotumab vedotin (2022) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Sandro Pignata?
Sandro Pignata is affiliated with the following schools:
